If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Synthesis == A chromatography-free synthesis of azidophenylalanine has been reported. It starts from L-phenylalanine and includes iodination to form 4-iodo-L-phenylalanine, followed by Boc protection, Cu(I)-catalyzed azidation using sodium azide (NaN3), deprotection with sulfuric acid, and purification by recrystallization. This method avoids explosion risks associated with earlier approaches.
=== Food labeling === For US food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of daily value. For vitamin E labeling purposes 100% of the daily value was 30 international units (IUs), but as of May 2016, it was revised to 15 mg "as alpha-tocopherol" to bring it into agreement with the RDA. A table of the old and new adult daily values is provided at Reference Daily Intake. European Union regulations require that labels declare energy, protein, fat, saturated fat, carbohydrates, sugars, and salt. Voluntary nutrients may be shown if present in significant amounts. Instead of daily values, amounts are shown as percent of reference intakes (RIs). For vitamin E, 100% RI was set at 12 mg in 2011.
For services to the community in Martlesham, Suffolk. Brian Francis Bryceland, Senior Executive Officer, Department of Social Security. Cyril Percy Bunn. For services to Journalism in Cornwall. Christine Dorothe Burges. For services to Young People in Edenbndge, Kent. John Christopher Burne, Voluntary Observer, Meteorological Office, Kent. Patricia Rose Burnett. For services to Service Families in Hereford. Susan Marilyn Burns. For services to the Rela Goldhill Lodge, London and to Young Disabled People. Herbert Roy Butler. For services to the community in Frome, Somerset. William Anthony Butler. For political service. Maxwell Charles Cadmore. For services to Health Care in Swansea, South Wales. Walter Rounsfell Cairns, lately Literature Director, Scottish Arts Council. For services to Literature. William Martin Calderbank. For services to the Engineering Industry. Joseph Graham Campbell. For services to the community. Reginald John Cann, lately Maintenance Supervisor, Crown Estate Commissioners. Harold Canning, Chairman, Wolverhampton and Walsall Committee for the Employment of People with Disabilities. For services to the Employment of Disabled People. Pamela Kathleen Cannon, Revenue Typist, Board of Inland Revenue. Peter Andrew Carruthers. For services to Sport for People with Disabilities. Mary Shane Casement. For services to the Rehabilitation of Offenders. Allan Lewis Chambers. For services to Agriculture. Derek Chambers, Senior Investigation Officer, Her Majesty's Board of Customs and Excise.
== Medical uses == Spironolactone is used in the treatment of heart failure with reduced ejection fraction (HFrEF), where evidence shows that it reduces the risk of heart failure hospitalisation and mortality when added to standard therapy. Multiple studies show that spironolactone improves left ventricular diastolic function in patients with heart failure with preserved ejection fraction HFpEF, though without benefits in death from any cause or overall hospitalisation. One randomised controlled trial showed a modest reduction in hospitalisation due to heart failure. A secondary analysis of TOPCAT suggested possible benefit in patients with both HFpEF and resistant hypertension, but this has not been confirmed in a prospective trial designed for this subgroup. Spironolactone is an effective fourth-line add-on therapy for lowering blood pressure in resistant hypertension that remains uncontrolled despite an ACE inhibitor or ARB, calcium channel blocker, and diuretic. It is also used to treat edematous conditions such as nephrotic syndrome or ascites in people with liver disease, essential hypertension, low blood levels of potassium, secondary hyperaldosteronism (such as occurs with liver cirrhosis), and Conn's syndrome (primary hyperaldosteronism). The most common use of spironolactone is in the treatment of heart failure. On its own, spironolactone is only a weak diuretic because it primarily targets the distal nephron (collecting tubule), where only small amounts of sodium are reabsorbed, but it can be combined with other diuretics to increase efficacy.
The Ukrainian General Staff said that Russia launched sixteen missiles and thirty five Shahed drones at Kyiv and other cities in Ukraine, injuring five people in Kyiv. Ukraine claimed to have shot down all drones. Other attacks occurred in the Kharkiv, Kherson, Mykolaiv and Odesa regions. Rocket fire was also reported along with airstrikes. Ukrainian Air Force spokesperson Colonel Yurii Ihnat said that there were "seven aircraft and up to eight launches of Kh-22 cruise missiles" at Odesa Oblast. Many of the missiles were believed to have self-destructed due to their age. One missile was believed to have hit a food storage warehouse in Odesa starting a fire. The missiles were fired from Tu-22 bombers. The attacks occurred on the eve of celebrations of Victory Day in Russia on 9 May. Russia again blocked grain exports from Ukraine, putting about 90 ships in waiting.
Sources: en.wikipedia.org
== History == Rosetta Genomics was founded by Isaac Bentwich in 2000 to pursue commercial applications of microRNA research. The company had its IPO on March 6, 2007, and is traded on the NASDAQ. Rosetta Genomics expects the funds raised to advance its microRNA-based diagnostic and therapeutic cancer products through initial clinical validation, defined as success in identifying the specific biomarker panels via blinded tests of samples supplied by medical institutions. In 2016, the company was ranked #27 on the Deloitte Fast 500 North America list. In 2017, the company was sold for $10 million to private US company Genoptix. On 31 May 2018, it was announced that Rosetta Genomics filed for Chapter 7 bankruptcy.
MEB-1170 is an atypical opioid receptor modulator which is under development for the treatment of pain and opioid use disorder. It is a highly biased agonist of the μ-opioid receptor (MOR) and appears to be biased for activation of G protein signaling over β-arrestin recruitment. Aside from the fact that it is a MOR biased agonist, the drug is said to be a MOR full agonist as well as a κ-opioid receptor (KOR) partial agonist and to have a unique pharmacological profile. It is taken orally. The drug produces robust analgesia in several assays similarly to morphine in rodents. However, in contrast to other MOR agonists like morphine and oliceridine, MEB-1170 is said to have not produced analgesic tolerance, sedation, respiratory depression, rewarding effects, or reinforcing effects and to have shown only minimal withdrawal symptoms. In addition, unlike morphine, but similarly to oliceridine, it negligibly affected gastrointestinal transit, a measure of constipation-like effect. As such, the drug is claimed to have greatly improved tolerability, safety, and misuse liability relative to conventional opioids like morphine. The toxicokinetics of MEB-1170 in rats and dogs have been described. It has a longer duration than morphine in rodents. MEB-1170 was first described in the news media in 2017 and in the scientific literature in 2018. It is being developed by Mebias Discovery. As of April 2023, the drug is in phase 1 clinical trials for treatment of pain and opioid use disorder. It is being developed for both prevention and treatment of opioid use disorder.
== Interactions == Fremanezumab does not interact with other antimigraine drugs such as triptans, ergot alkaloids and analgesics. It is expected to generally have a low potential for interactions, because it is not metabolized by cytochrome P450 enzymes.
Other sensory components include "the smell of the Black Forest" that accompanies a kirsch ice cream. In 2023, the Fat Duck introduced its 12-dish Sensorium menu, which the Times said was more conventional and "dials down the trickery and sleights of hand". It incorporates new seasonal dishes alongside previous dishes such as the Sound of Sea and A Walk in the Woods ("an edible forest floor of mushrooms, blackberries and beetroot").
==== Materials, incubation and viability ==== Polydimethylsiloxane (PDMS) is the most common material to fabricate microfluidic devices due to low cost, ease of prototyping, and good gas permeability. Along with perfluorocarbon carrier oils, which also allow good gas permeability, used as a continuous phase in the droplet-based microfluidic system for cell culture, some studies have found that cell viability is comparable to culture in flasks, for example mammalian cells. To reach the required culture time, a reservoir or a delay line can be used. Using a reservoir allows long-term culture from several hours to several days while the delay line is suitable for short-term culture with several minutes. Incubation is feasible both on-chip (reservoir connected with a microfluidic system or delay lines) and off-chip (PTFE tubing isolated with a microfluidic system) after the droplets formed. After incubation, droplets can be reinjected into the microfluidic device for analysis. There are also specially designed on-chip droplet storage systems for direct analysis, such as the "dropspot" device, which stores droplets in several array chambers and uses microarray scanner for direct analysis.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.